enVVeno Medical (NASDAQ:NVNO) Upgraded by LADENBURG THALM/SH SH to “Strong-Buy” Rating

enVVeno Medical (NASDAQ:NVNO) was upgraded by analysts at LADENBURG THALM/SH SH from a “hold” rating to a “strong-buy” rating in a report released on Monday,Zacks.com reports.

Separately, Weiss Ratings downgraded enVVeno Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. According to MarketBeat, enVVeno Medical has an average rating of “Moderate Buy”.

enVVeno Medical Price Performance

NASDAQ:NVNO traded up $0.29 during mid-day trading on Monday, hitting $11.39. 10,348 shares of the company’s stock were exchanged, compared to its average volume of 15,843. enVVeno Medical has a one year low of $8.67 and a one year high of $196.70. The business has a fifty day moving average price of $10.62 and a 200 day moving average price of $10.95. The company has a market cap of $7.63 million, a PE ratio of -0.45 and a beta of 1.09.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($5.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($8.40) by $2.51.

Institutional Trading of enVVeno Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in enVVeno Medical by 1.1% in the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock worth $796,000 after buying an additional 2,211 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of enVVeno Medical during the second quarter valued at approximately $51,000. Creative Planning purchased a new stake in shares of enVVeno Medical during the second quarter valued at approximately $54,000. ACT Capital Management LLC bought a new stake in shares of enVVeno Medical during the fourth quarter valued at approximately $37,000. Finally, Kingdon Capital Management L.L.C. increased its position in shares of enVVeno Medical by 58.2% during the third quarter. Kingdon Capital Management L.L.C. now owns 1,359,261 shares of the company’s stock valued at $1,232,000 after acquiring an additional 500,000 shares in the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Company Profile

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.